Epstein-Barr Virus Replication Within Pulmonary Epithelial Cells in Cryptogenic Fibrosing Alveolitis

Overview

Journal Thorax

Date 1995 Dec 1

PMID 8553293

Citations 62

Authors

J J Egan

J P Stewart

P S Hasleton

J R Arrand

K B Carroll

A A Woodcock

Affiliations

Soon will be listed here.

Abstract

Background: Cryptogenic fibrosing alveolitis (synonymous with idiopathic pulmonary fibrosis) is a clinically heterogeneous condition in which the precipitating factor is unclear. Both environmental and infective factors have been implicated. An association between Epstein-Barr virus (EBV) and cryptogenic fibrosing alveolitis was suggested over a decade ago by a study based on EBV serology, but the significance of this has been unclear.

Methods: Lung tissue obtained surgically from patients (n = 20) with cryptogenic fibrosing alveolitis was investigated for evidence of EBV replication and compared with lung tissue from 21 control patients. Fourteen of the 20 patients had received no specific therapy for cryptogenic fibrosing alveolitis at the time of biopsy. Monoclonal antibodies directed against the EBV viral antigens, EBV viral capsid antigen (VCA) and gp 340/220 antigen, which are expressed during the lytic phase of the EBV life cycle, were studied.

Results: Fourteen (70%) of the 20 patients with cryptogenic fibrosing alveolitis were positive for both EBV VCA and gp 340/220 compared with two (9%) of the 21 controls. In the patients with cryptogenic fibrosing alveolitis viral replication was localised to pulmonary epithelial cells using epithelial cell markers, and immunohistochemical analysis confirmed the staining to be within type II alveolar cells.

Conclusions: This is the first report of in vivo EBV replication within epithelial cells of the lower respiratory tract in an immunocompetent human host. Furthermore, this suggests that EBV may be an immune trigger or contribute to lung injury in cryptogenic fibrosing alveolitis, thus offering a potential new avenue of treatment.

Citing Articles

Current and Novel Treatment Modalities of Idiopathic Pulmonary Fibrosis.

Arshad M, Athar Z, Hiba T Cureus. 2024; 16(3):e56140.

PMID: 38618480 PMC: 11015429. DOI: 10.7759/cureus.56140.

Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.

Adegunsoye A, Kropski J, Behr J, Blackwell T, Corte T, Cottin V Am J Respir Crit Care Med. 2024; 210(4):401-423.

PMID: 38573068 PMC: 11351799. DOI: 10.1164/rccm.202401-0238SO.

Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.

Lai Y, Wei X, Ye T, Hang L, Mou L, Su J Front Immunol. 2021; 12:747335.

PMID: 34804029 PMC: 8602099. DOI: 10.3389/fimmu.2021.747335.

The Role of Herpes Viruses in Pulmonary Fibrosis.

Duckworth A, Longhurst H, Paxton J, Scotton C Front Med (Lausanne). 2021; 8:704222.

PMID: 34368196 PMC: 8339799. DOI: 10.3389/fmed.2021.704222.

Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features.

Galioto F, Palmucci S, Astuti G, Vancheri A, Distefano G, Tiralongo F Diagnostics (Basel). 2020; 10(7).

PMID: 32635390 PMC: 7399856. DOI: 10.3390/diagnostics10070450.

References

Jimenez S . New insights into the pathogenesis of interstitial pulmonary fibrosis. Thorax. 1994; 49(3):193-5. PMC: 1021143. DOI: 10.1136/thx.49.3.193. View

Niedobitek G, Young L, Lau R, Brooks L, Greenspan D, Greenspan J . Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol. 1991; 72 ( Pt 12):3035-46. DOI: 10.1099/0022-1317-72-12-3035. View

Niedobitek G, Young L . Epstein-Barr virus persistence and virus-associated tumours. Lancet. 1994; 343(8893):333-5. DOI: 10.1016/s0140-6736(94)91167-3. View

Howe J, Steitz J . Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci U S A. 1986; 83(23):9006-10. PMC: 387063. DOI: 10.1073/pnas.83.23.9006. View

Hoffman G, Lazarowitz S, Hayward S . Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980; 77(5):2979-83. PMC: 349530. DOI: 10.1073/pnas.77.5.2979. View

Lung M, Lam W, So S, Lam W, Chan K, Ng M . Evidence that respiratory tract is major reservoir for Epstein-Barr virus. Lancet. 1985; 1(8434):889-92. DOI: 10.1016/s0140-6736(85)91671-x. View

Carrigan D, Drobyski W, Russler S, Tapper M, Knox K, Ash R . Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet. 1991; 338(8760):147-9. DOI: 10.1016/0140-6736(91)90137-e. View

MacMahon E, Glass J, Hayward S, Mann R, Becker P, CHARACHE P . Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991; 338(8773):969-73. DOI: 10.1016/0140-6736(91)91837-k. View

Hoffmann D, Gedebou M, Jimenez A, Nichols W, Marchevsky A . Detection of Epstein-Barr virus by polymerase chain reaction in transbronchial biopsies of lung transplant recipients: evidence of infection?. Mod Pathol. 1993; 6(5):555-9. View

10.

Millar A, Patou G, Miller R, Grundy J, Katz D, Weller I . Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger?. Am Rev Respir Dis. 1990; 141(6):1474-7. DOI: 10.1164/ajrccm/141.6.1474. View

11.

Matsui R, Goldstein R, Mihal K, BRODY J, Steele M, Fine A . Type I collagen formation in rat type II alveolar cells immortalised by viral gene products. Thorax. 1994; 49(3):201-6. PMC: 1021146. DOI: 10.1136/thx.49.3.201. View

12.

Ashcroft T, Simpson J, Timbrell V . Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988; 41(4):467-70. PMC: 1141479. DOI: 10.1136/jcp.41.4.467. View

13.

Holmes G, Kaplan J, Stewart J, Hunt B, Pinsky P, Schonberger L . A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?. JAMA. 1987; 257(17):2297-302. View

14.

Sunil-Chandra N, Efstathiou S, Arno J, Nash A . Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J Gen Virol. 1992; 73 ( Pt 9):2347-56. DOI: 10.1099/0022-1317-73-9-2347. View

15.

Billings C, Howard P . Hypothesis: exposure to solvents may cause fibrosing alveolitis. Eur Respir J. 1994; 7(6):1172-6. View

16.

Henle W, Henle G . Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res. 1981; 41(11 Pt 1):4222-5. View

17.

Gosselin J, Menezes J, DAddario M, Hiscott J, Flamand L, Lamoureux G . Inhibition of tumor necrosis factor-alpha transcription by Epstein-Barr virus. Eur J Immunol. 1991; 21(1):203-8. DOI: 10.1002/eji.1830210130. View

18.

Stewart J, Hampson I, Heinrich H, Mackett M, Arrand J . Enhanced expression of the Epstein-Barr virus latent membrane protein by a recombinant vaccinia virus. J Gen Virol. 1989; 70 ( Pt 5):1231-7. DOI: 10.1099/0022-1317-70-5-1231. View

19.

Revoltella R, Vigneti E, Fruscalzo A, Park M, Ragona G, Rocchi G . Epstein-Barr virus DNA sequences in precursor monocyte-macrophage cell lines established from the bone marrow of children with maturation defects of haematopoiesis. J Gen Virol. 1989; 70 ( Pt 5):1203-15. DOI: 10.1099/0022-1317-70-5-1203. View

20.

Vergnon J, Vincent M, de The G, Mornex J, Weynants P, Brune J . Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?. Lancet. 1984; 2(8406):768-71. DOI: 10.1016/s0140-6736(84)90702-5. View